

SmartPA Criteria Proposal

Drug/Drug Class:	Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit
First Implementation Date:	November 18, 2010
Proposed Date:	October 17, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of serotonin-norepinephrine reuptake inhibitor (SNRI) agents

Why Issue Selected: MO HealthNet will assess the usage of SNRI agents in the pharmacy program with a primary goal of patient safety. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and without a clinical edit it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. By using medical evidence guidelines, this clinical edit can flag potentially dangerous duplicate and high dose therapy for SNRI agents. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Program-Specific Information:

Date Range FFS 7-1-2022 to 6-30-2023				
Generic Equivalent	Drug Description	Claims	Spend	Avg Spend per Claim
DESVENLAFAXINE	DESVENLAFAXINE ER 50 MG TAB	22	\$2,567.20	\$116.69
	DESVENLAFAXINE ER 100 MG TAB	90	\$11,478.83	\$127.54
	PRISTIQ ER 25 MG TABLET	1186	\$31,969.14	\$26.96
	PRISTIQ ER 50 MG TABLET	4095	\$108,178.51	\$26.42
	PRISTIQ ER 100 MG TABLET	5431	\$150,024.67	\$27.62
DULOXETINE	CYMBALTA 20 MG CAPSULE	10355	\$164,161.67	\$15.85
	CYMBALTA 30 MG CAPSULE	52100	\$785,426.04	\$15.08
	CYMBALTA 60 MG CAPSULE	86,998	\$1,376,661.67	\$15.82
	DRIZALMA SPRINKLE DR 20 MG CAP	0	-	-
	DRIZALMA SPRINKLE DR 30 MG CAP	0	-	-
	DRIZALMA SPRINKLE DR 40 MG CAP	0	-	-
	DRIZALMA SPRINKLE DR 60 MG CAP	0	-	-
LEVOMILNACIPRAN	IRENKA DR 40 MG CAPSULE	707	\$52,094.83	\$73.68
	FETZIMA ER 20 MG CAPSULE	194	\$119,061.88	\$613.72
	FETZIMA ER 40 MG CAPSULE	339	\$165,307.81	\$487.63
	FETZIMA ER 80 MG CAPSULE	326	\$140,055.50	\$429.62
	FETZIMA ER 120 MG CAPSULE	392	\$172,407.45	\$439.81
MILNACIPRAN	FETZIMA 20-40 MG TITRATION PAK	5	\$2,211.35	\$442.27
	SAVELLA 12.5 MG TABLET	38	\$12,090.36	\$318.17
	SAVELLA 25 MG TABLET	96	\$37,658.86	\$392.28
	SAVELLA 50 MG TABLET	619	\$231,247.74	\$373.58

	SAVELLA 100 MG TABLET	446	\$171,688.24	\$384.95
	SAVELLA TITRATION PACK	26	\$9,635.59	\$370.60
VENLAFAXINE	EFFEXOR 25 MG TABLET	462	\$6,474.45	\$14.01
	EFFEXOR 37.5MG TABLET	2440	\$33,144.64	\$13.58
	EFFEXOR 50MG TABLET	618	\$8,903.76	\$14.41
	EFFEXOR 75MG TABLET	3875	\$56,759.25	\$14.65
	EFFEXOR 100MG TABLET	1167	\$18,733.33	\$16.05
VENLAFAXINE ER	VENLAFAXINE BES ER 112.5 MG TB	1	\$197.49	\$197.49
	VENLAFAXINE HCL ER 37.5 MG TAB	162	\$10,647.14	\$65.72
	VENLAFAXINE HCL ER 75 MG TAB	596	\$39,121.07	\$65.64
	VENLAFAXINE HCL ER 150 MG TAB	1143	\$41,652.50	\$36.44
	VENLAFAXINE HCL ER 225 MG TAB	4829	\$290,019.91	\$60.06
	EFFEXOR XR 37.5 MG CAPSULE	17088	\$251,061.46	\$14.69
	EFFEXOR XR 75 MG CAPSULE	38801	\$590,934.18	\$15.23
	EFFEXOR XR 150 MG CAPSULE	40714	\$643,977.25	\$15.82
Total		275,361	\$5,735,553.77	\$20.83

Type of Criteria: ☐ Increased risk of ADE
☒ Appropriate Indications

☐ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Serotonin-norepinephrine reuptake inhibitor (SNRI) agents
- Age range: All appropriate MO HealthNet participants aged 5 years and older

Approval Criteria

- Participant aged 5 years or older **AND**
- Documented compliance to current SNRI therapy regimen (90 days in the past 120 days) **OR**
- Documented appropriate diagnosis required for:
 - Participants < 18 years of age **OR**
 - Participants < 26 years of age who are also enrolled in foster care
- For diagnosis of major depressive disorder: all SNRI agents except Savella
- For diagnosis of fibromyalgia: duloxetine agents or Savella only
- For diagnosis of chronic musculoskeletal pain or diabetic peripheral neuropathic pain: duloxetine agents only
- For diagnosis of generalized anxiety disorder: duloxetine or venlafaxine agents only
- For diagnosis of social anxiety disorder, panic disorder, or migraine: venlafaxine agents only
- For Fetzima: documented therapeutic trial of generic Cymbalta or Effexor XR
- For venlafaxine ER tablets and desvenlafaxine ER tablets: documented reason why participant cannot utilize generic Effexor XR capsules
- **For duloxetine sprinkle capsules or 40 mg capsules: Clinical Consultant Review documented reason why participant cannot utilize generic Cymbalta capsules**

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosage limits (see Appendix A)
- Participants < 18 years of age: history of > 2 SNRI agents for more than 30 days in the past 90 days
- Participants ≥ 18 years of age: history of > 2 SNRI agents for more than 60 days in the past 90 days
- Participant is on more than one SSRI agent and one SNRI agent concurrently for more than 30 days

Required Documentation

Laboratory Results:
MedWatch Form:

☐
☐

Progress Notes:
Other:

☐
☒

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

Appendix A – Maximum Daily Dosage Limits

Generic Equivalent	Max Daily Dose
DESVENLAFAXINE	400 MG
DULOXETINE	120 MG
LEVOMILNACIPRAN	120 MG
MILNACIPRAN	200 MG
VENLAFAXINE	375 MG
VENLAFAXINE ER	225 MG

Drug Description	Generic Equivalent	Dose Optimization Calculation
CYMBALTA 20 MG	DULOXETINE	Deny dosing more frequently than 2 per day
CYMBALTA 30 MG	DULOXETINE	Deny dosing more frequently than 2 per day
CYMBALTA 60 MG	DULOXETINE	Deny dosing more frequently than 2 per day
DESVENLAFAXINE ER 100MG	DESVENLAFAXINE	Deny dosing more frequently than 4 per day
DESVENLAFAXINE ER 50MG	DESVENLAFAXINE	Deny dosing more frequently than 1 per day
DRIZALMA SPRINKLE 20 MG	DULOXETINE	Deny dosing more frequently than 1 per day
DRIZALMA SPRINKLE 30 MG	DULOXETINE	Deny dosing more frequently than 1 per day
DRIZALMA SPRINKLE 40 MG	DULOXETINE	Deny dosing more frequently than 2 per day
DRIZALMA SPRINKLE 60 MG	DULOXETINE	Deny dosing more frequently than 2 per day
DULOXETINE DR 40 MG	DULOXETINE	Deny dosing more frequently than 2 per day
EFFEXOR XR 150 MG	VENLAFAXINE HCL	Deny dosing more frequently than 2 per day
EFFEXOR XR 37.5 MG	VENLAFAXINE HCL	Deny dosing more frequently than 2 per day
EFFEXOR XR 75 MG	VENLAFAXINE HCL	Deny dosing more frequently than 3 per day
PRISTIQ 100MG	DESVENLAFAXINE	Deny dosing more frequently than 4 per day
PRISTIQ 25MG	DESVENLAFAXINE	Deny dosing more frequently than 1 per day
PRISTIQ 50MG	DESVENLAFAXINE	Deny dosing more frequently than 1 per day
SAVELLA 100 MG TABLET	MILNACIPRAN	Deny dosing more frequently than 2 per day
SAVELLA 12.5 MG TABLET	MILNACIPRAN	Deny dosing more frequently than 2 per day
SAVELLA 25 MG TABLET	MILNACIPRAN	Deny dosing more frequently than 2 per day
SAVELLA 50 MG TABLET	MILNACIPRAN	Deny dosing more frequently than 2 per day
VENLAFAXINE ER 112.5 MG TAB	VENLAFAXINE BES	Deny dosing more frequently than 1 per day
VENLAFAXINE ER 150 MG TAB	VENLAFAXINE HCL	Deny dosing more frequently than 1 per day
VENLAFAXINE ER 225 MG TAB	VENLAFAXINE HCL	Deny dosing more frequently than 1 per day
VENLAFAXINE ER 37.5 MG TAB	VENLAFAXINE HCL	Deny dosing more frequently than 1 per day
VENLAFAXINE ER 75 MG TAB	VENLAFAXINE HCL	Deny dosing more frequently than 1 per day

References

- Facts & Comparisons. Serotonin and Norepinephrine Reuptake Inhibitors. Accessed September 11, 2023.

DRAFT